Physician profile
Faisal Usman
NPI 1194011908
$2,102.72
in general payments reported to CMS, 2019-2025
24 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $205 · 2021: $248 · 2022: $389 · 2023: $603 · 2024: $232 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $981 · Education: $67.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $980.69 |
| Education | $67.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.54 | 2019-2024 | Ofev |
| Astrazeneca Pharmaceuticals LP | $246.97 | 2019-2023 | Breztri, Fasenra |
| Amgen INC. | $232.28 | 2022-2023 | Tezspire |
| Philips North America LLC | $165.39 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $140.29 | 2020-2024 | Opsumit, Uptravi |
| Inspire Medical Systems, INC. | $134.38 | 2023-2025 | Inspire |
| Medtronic, INC. | $121.32 | 2022-2024 | Endurant Iis, Illumisite, Valiant Captivia |
| Regeneron Healthcare Solutions, INC. | $89.22 | 2020-2022 | |
| Pulmonx Corporation | $83.24 | 2025 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Genzyme Corporation | $76.52 | 2023 | |
| Insmed, INC. | $75.05 | 2022-2025 | Arikayce, Brinsupri |
| Glaxosmithkline, LLC. | $71.71 | 2019-2024 | Nucala |
| Alexion Pharmaceuticals, INC. | $50.00 | 2024 | Ultomiris |
| Circassia INC. | $36.84 | 2019-2020 | |
| Vapotherm INC | $33.57 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $32.69 | 2025 | |
| Ambu INC. | $31.64 | 2023 | |
| Merck Sharp & Dohme LLC | $31.36 | 2023 | |
| Sunovion Pharmaceuticals INC. | $29.89 | 2019 | |
| Liquidia Technologies, INC. | $26.94 | 2025 | Yutrepia |
| Harmony Biosciences LLC | $23.82 | 2024 | |
| Zoll Respicardia, INC. | $18.73 | 2025 | Remede System |
| Inogen, INC. | $17.25 | 2023 | Inogen |
| Icu Medical INC | $16.08 | 2024 | Tracheostomy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faisal Usman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.